Share This Article:

Risk Assessment Using Two Different Diagnostic Tools: Metabolic Syndrome and Cardiovascular Risk Score (SCORE)—Data from a Weight Reduction Intervention Study

Abstract Full-Text HTML Download Download as PDF (Size:279KB) PP. 1028-1036
DOI: 10.4236/fns.2013.410134    4,145 Downloads   5,215 Views   Citations


Objective: Risk score models and the diagnosis of a metabolic syndrome are useful for cardiovascular (CV) risk prediction. The identification of individuals with high CV and metabolic risk is essential to provide appropriate prevention and therapy. The present study aims at clarifying whether these indicators are altered by a weight reduction programme. Additionally, which diagnostic tool has a better predictive value is examined. Method: One hundred and twenty overweight and obese subjects aged 30 60 years were included in a 12-week weight reduction programme. The CV risk was assessed by means of German multiple-used risk charts (SCORE) at baseline and at the end of the trial. Furthermore, the prevalence of the metabolic syndrome (three out of five risk factors) was quantified. Results: The initial prevalence of the metabolic syndrome was 63.3% (n = 76) and decreased to 41.7% (n = 50) by the end of the intervention. The SCORE also decreased significantly after twelve weeks (p < 0.001). The percentage of subjects at high risk (SCORE > 5%) was comparatively low (t0: 7.4%, n = 7; t12: 5.3%, n = 5). Conclusion: The weight reduction concept was applicable to improve the CV risk SCORE and decrease the prevalence of the metabolic syndrome. The CV 10-year risk calculated using German risk charts (SCORE) probably underestimated the risk of CV diseases in this collective. In this case, the diagnosis of a metabolic syndrome is more meaningful than risk SCORE calculations.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

J. Willers and A. Hahn, "Risk Assessment Using Two Different Diagnostic Tools: Metabolic Syndrome and Cardiovascular Risk Score (SCORE)—Data from a Weight Reduction Intervention Study," Food and Nutrition Sciences, Vol. 4 No. 10, 2013, pp. 1028-1036. doi: 10.4236/fns.2013.410134.


[1] C. R. Balistreri, C. Caruso and G. Candore, “The Role of Adipose Tissue and Adipokines in Obesity-Related Inflammatory Diseases,” Mediators of Inflammation, 2010, Article ID 802078.
[2] S. L. Doyle, C. L. Donohoe, J. Lysaght and J. V. Reynolds, “Visceral Obesity, Metabolic Syndrome, Insulin Resistance and Cancer,” Proceedings of the Nutrition Society, Vol. 71, No. 1, 2012, pp. 181-189.
[3] C. L. Donohoe, S. L. Doyle and J. V. Reynolds, “Visceral Adiposity, Insulin Resistance and Cancer Risk,” Diabetology & Metabolic Syndrome, Vol. 3, 2011, p. 12.
[4] M. A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang and R. H. Eckel, “The Metabolic Syndrome,” Endocrine Reviews, Vol. 29, No. 7, 2008, pp. 777-822.
[5] P. Maison, C. D. Byrne, C. N. Hales, N. E. Day and N. J. Wareham, “Do Different Dimensions of the Metabolic Syndrome Change Together Over Time? Evidence Supporting Obesity as the Central Feature,” Diabetes Care, Vol. 24, No. 10, 2001, pp. 1758-1763.
[6] A. Koster, S. Stenholm, D. E. Alley, L. J. Kim, E. M. Simonsick, A. M. Kanaya, M. Visser, D. K. Houston, B. J. Nicklas, F. A. Tylavsky, S. Satterfield, B. H. Goodpaster, L. Ferrucci and T. B. Harris, “Health ABC Study. Body Fat Distribution and Inflammation among Obese Older Adults with and without Metabolic Syndrome,” Obesity (Silver Spring), Vol. 18, No. 12, 2010, pp. 2354-2361.
[7] A. J. Cameron, D. W. Dunstan, N. Owen, P. Z. Zimmet, E. L. Barr, A. M. Tonkin, D. J. Magliano, S. G. Murray, T. A. Welborn and J. E. Shaw, “Health and Mortality Consequences of Abdominal Obesity: Evidence from the AusDiab Study,” Medical Journal of Australia, Vol. 191, No. 4, 2009, pp. 202-208.
[8] S.A Ritchie and J. M. Connell, “The Link between Abdominal Obesity, Metabolic Syndrome and Cardiovascular Disease,” Nutrition, Metabolism & Cardiovascular Diseases, Vol. 17, No. 4, 2007, pp. 319-326.
[9] B. Isomaa, P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, M. R. Taskinen and L. Groop, “Cardiovascular Morbidity and Mortality Associated with the Metabolic Syndrome,” Diabetes Care, Vol. 24, No. 4, 2001, pp. 683-689.
[10] P. W. Wilson, R. B. D’Agostino, D. Levy, A. M. Belanger, H. Silbershatz and W. B. Kannel, “Prediction of Coronary Heart Disease Using Risk Factor Categories,” Circulation, Vol. 97, No. 18, 1998, pp. 1837-1847.
[11] G. Assmann, P. Cullen and H. Schulte, “Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Munster (PROCAM) Study,” Circulation, Vol. 105, No. 3, 2002, pp. 310-315.
[12] R. M. Conroy, K. Pyorala, A. P. Fitzgerald, S. Sans, A. Menotti, B. G. De, P. Ducimetiere, P. Jousilahti, U. Keil, I. Njolstad, R. G. Oganov, T. Thomsen, H. Tunstall-Pedoe, A. Tverdal, H. Wedel, P. Whincup, L. Wilhelmsen and I. M. Graham, “Estimation of Ten-Year Risk of Fatal Cardiovascular Disease in Europe: The SCORE Project,” European Heart Journal, Vol. 24, No. 11, 2003, pp. 9871003.
[13] U. Keil, A. Fitzgerald, H. Gohlke, J. Wellmann and H. Hense, “Risk Stratification of Cardiovascular Diseases in Primary Prevention—The New SCORE-Deutschland Risk Charts,” Deutsches Arzteblatt, Vol. 102, No. 25, 2005, pp. A1808-A1812.
[14] R. E. Schmieder, M. Goebel and P. Bramlage, “Barriers to Cardiovascular Risk Prevention and Management in Germany—An Analysis of the EURIKA Study,” Journal of Vascular Health and Risk Management, Vol. 8, 2012, pp. 177-186.
[15] C. C. Case, P. H. Jones, K. Nelson, S. E. O’Brian and C. M. Ballantyne, “Impact of Weight Loss on the Metabolic Syndrome,” Diabetes, Obesity and Metabolism, Vol. 4, No. 6, 2002, pp. 407-414.
[16] P. Ilanne-Parikka, J. G. Eriksson, J. Lindstrom, M. Peltonen, S. Aunola, H. Hamalainen, S. Keinanen-Kiukaanniemi, M. Laakso, T. T. Valle, J. Lahtela, M. Uusitupa and J. Tuomilehto, “Effect of Lifestyle Intervention on the Occurrence of Metabolic Syndrome and Its Components in the Finnish Diabetes Prevention Study,” Diabetes Care, Vol. 31, No. 4, 2008, pp. 805-807.
[17] A. Ferland and R. H. Eckel, “Does Sustained Weight Loss Reverse the Metabolic Syndrome?” Current Hypertension Reports, Vol. 13, No. 6, 2011, pp. 456-464.
[18] J. Willers, S. Plotz and A. Hahn, “The Combination of a High-Protein Formula Diet and Polyglucosamine Decreases Body Weight and Parameters of Glucose and Lipid Metabolism in Overweight and Obese Men and Women,” European Journal of Food Research & Review, Vol. 2, No. 1, 2012, pp. 29-45.
[19] NCEP ATP-III, “Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report,” Circulation, Vol. 106, No. 25, 2002, pp. 3143-3421.
[20] K. G. Alberti, R. H. Eckel, S. M. Grundy, P. Z. Zimmet, J. I. Cleeman, K. A. Donato, J. C. Fruchart, W. P. James, C. M. Loria and S. C. Smith, “Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,” Circulation, Vol. 120, No. 16, 2009, pp. 1640-1645.
[21] R. Weiss, J. Dziura, T. S. Burgert, W. V. Tamborlane, S. E. Taksali, C. W. Yeckel, K. Allen, M. Lopes, M. Savoye, J. Morrison, R. S. Sherwin and S. Caprio, “Obesity and the Metabolic Syndrome in Children and Adolescents,” The New England Journal of Medicine, Vol. 350, No. 23, 2004, pp. 2362-2374.
[22] H. Neuhauser and U. Ellert, “Estimation of the Metabolic Syndrome Prevalence in the General Population in Germany,” Journal of Public Health, Vol. 16, No. 3, 2008, pp. 221-227.
[23] E. S. Ford, W. H. Giles and W. H. Dietz, “Prevalence of the Metabolic Syndrome among US Adults: Findings from the Third National Health and Nutrition Examination Survey,” JAMA, Vol. 287, No. 3, 2002, pp. 356-359.
[24] S. Moebus, J. Hanisch, P. Bramlage, C. Losch, H. Hauner, J. Wasem and K. H. Jockel, “Regional Differences in the Prevalence of the Metabolic Syndrome in Primary Care Practices in Germany,” Deutsches Arzteblatt International, Vol. 105, No. 12, 2008, pp. 207-213.
[25] S. Moebus, J. U. Hanisch, M. Neuhauser, P. Aidelsburger, J. Wasem and K. H. Jockel, “Assessing the Prevalence of the Metabolic Syndrome According to NCEP ATP III in Germany: Feasibility and Quality Aspects of a Two Step Approach in 1550 Randomly Selected Primary Health Care Practices,” German Medical Science, Vol. 4, 2006, Doc07.
[26] S. S. Daskalopoulou, D. P. Mikhailidis and M. Elisaf, “Prevention and Treatment of the Metabolic Syndrome,” Angiology, Vol. 55, No. 6, 2004, pp. 589-612.
[27] D. Konig, P. Deibert, I. Frey, U. Landmann and A. Berg, “Effect of Meal Replacement on Metabolic Risk Factors in Overweight and Obese Subjects,” Annals of Nutrition and Metabolism, Vol. 52, No. 1, 2008, pp. 74-78.
[28] L. J. Joseph, R. L. Prigeon, J. B. Blumenthal, A. S. Ryan and A. P. Goldberg, “Weight Loss and Low-Intensity Exercise for the Treatment of Metabolic Syndrome in Obese Postmenopausal Women,” Journals of Gerontology Series A: Biological Sciences and Medical Sciences, Vol. 66, No. 9, 2011, pp. 1022-1029.
[29] S. Moebus, J. U. Hanisch, C. Losch, P. Bramlage, H. Schunkert, H. Hauner, J. Wasem and K. H. Jockel, “Arterial Hypertension and Abdominal Obesity Are the Most Important Factors of the Metabolic Syndrome in a Cohort of 35,869 Patients in Primary Care,” Journal of Hypertension, Vol. 12, No. 2, 2008, pp. 7-11.
[30] H. Schunkert, S. Moebus, J. Hanisch, P. Bramlage, E. Steinhagen-Thiessen, H. Hauner, J. Weil, J. Wasem and K. H. Jockel, “The Correlation between Waist Circumference and ESC Cardiovascular Risk Score: Data from the German Metabolic and Cardiovascular Risk Project (GEMCAS),” Clinical Research in Cardiology, Vol. 97, No. 11, 2008, pp. 827-835.
[31] H. Ulmer, B. Kollerits, C. Kelleher, G. Diem and H. Concin, “Predictive Accuracy of the SCORE Risk Function for Cardiovascular Disease in Clinical Practice: A Prospective Evaluation of 44,649 Austrian Men and Women,” European Journal of Cardiovascular Prevention & Rehabilitation, Vol. 12, No. 5, 2005, pp. 433-441.
[32] A. S. Lindman, M. B. Veierod, J. I. Pedersen, A. Tverdal, I. Njolstad and R. Selmer, “The Ability of the SCORE High-Risk Model to Predict 10-Year Cardiovascular Disease Mortality in Norway,” European Journal of Cardiovascular Prevention & Rehabilitation, Vol. 14, No. 4, 2007, pp. 501-507.
[33] J. Levesque and B. Lamarche, “The Metabolic Syndrome: Definitions, Prevalence and Management,” Journal of Nutrigenetics and Nutrigenomics, Vol. 1, No. 3, 2008, pp. 100-108.
[34] P. W. Wilson, R. B. D’Agostino, H. Parise, L. Sullivan and J. B. Meigs, “Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus,” Circulation, Vol. 112, No. 20, 2005, pp. 3066-3072.
[35] S. Tonstad and I. Hjermann, “A High Risk Score for Coronary Heart Disease Is Associated with the Metabolic Syndrome in 40-Year-Old Men and Women,” Journal of Cardiovascular Risk, Vol. 10, No. 2, 2003, pp. 129-135.
[36] J. Postler, A. Bosy-Westphal, B. Hitze, M. Pfeuffer and M. J. Müller, “Vergleich Dreier Kardiovaskularer RisikoScores (Framingham-Score, PROCAM-Score, SCOREDeutschland) und des Metabolischen Syndroms bei Erwachsenen der Kieler Adipositas-Praventionsstudie (KOPS),” Aktuellen Ernahrungsmedizin, Vol. 32, 2007, pp. 307-314.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.